Treatment of conditions through modulation of the autonomic nervous system

• US 20050153885A1
• Filed: 10/07/2004
• Published: 07/14/2005
• Est. Priority Date: 10/08/2003
• Status: Abandoned Application

• Current Assignee: Palo Alto Investors
• Original Assignee: Palo Alto Investors
• Inventors: Lee, Patrick Yuarn-Bor, Yun, Anthony Joonkyoo
• Application Number:
  US10/962,190
• Publication Number:
  US 20050153885A1
• Time in Patent Office: Days
• US Class Current: 424/697
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients

Abstract

Methods are provided for treating a subject for a condition caused by an abnormality in the subject'"'"'s autonomic nervous system. In accordance with the subject methods, at least a portion of a subject'"'"'s autonomic nervous system is pharmacologically modulated with at least one aldosterone antagonist in a manner that is effective to treat the subject for the condition. Also provided are systems and kits for use in practicing the subject methods.

Claims

1. A method of treating a subject for a condition caused by an autonomic nervous system abnormality comprising modulating at least a portion of said subject'"'"'s autonomic nervous system by administering an effective amount of at least one aldosterone antagonist or analogue thereof to said subject to treat said subject for at least one of:

cardiac rhythm disorders;

atherosclerosis;

coronary artery disease;

hyperlipidemia;

neurodegenerative conditions;

neuroinflammatory conditions;

orthopedic inflammatory conditions;

lymphoproliferative conditions;

autoimmune conditions;

inflammatory conditions;

infectious diseases, pulmonary conditions;

transplant-related conditions, gastrointestinal conditions;

endocrine conditions;

genitourinary conditions;

aging associated conditions;

neurologic conditions;

Th-2 dominant conditions;

conditions that cause hypoxia;

conditions that cause hypercarbia;

conditions that cause hypercapnia;

conditions that cause acidosis;

conditions that cause academia, pediatric-related conditions;

pregnancy conditions, OB-GYN conditions, sudden death syndromes, cancer;

fibrosis;

post-operative recovery conditions;

post-procedural recovery conditions;

chronic pain;

disorders of thermoregulation;

cyclic vomiting syndrome;

an autonomic dysregulation condition; and

trauma.

2. The method according to claim 1, wherein said modulation results in a sympathetic bias in at least a portion of said autonomic nervous system.

3. The method of claim 2, wherein said abnormality is characterized by a sympathetic bias.

4. The method of claim 2, wherein said abnormality is characterized by a parasympathetic bias.

5. The method according to claim 1, wherein said modulation results in a parasympathetic bias in at least a portion of said autonomic nervous system.

6. The method of claim 5, wherein said abnormality is characterized by a sympathetic bias.

7. The method of claim 5, wherein said abnormality is characterized by a parasympathetic bias.

8. The method according to claim 1, wherein said modulating results in a substantially equal parasympathetic and sympathetic functions in at least a portion of said autonomic nervous system.

9. The method of claim 8, wherein said abnormality is characterized by a sympathetic bias.

10. The method of claim 8, wherein said abnormality is characterized by a parasympathetic bias.

20. The method of claim 10, further comprising increasing said parasympathetic activity.

21. The method of claim 1, wherein said at least one aldosterone antagonist is chosen from spironolactone and eplerenone.

22. The method of claim 1, wherein said method comprises increasing the parasympathetic activity/sympathetic activity ratio in at least a portion of said subject'"'"'s autonomic nervous system.

23. The method of claim 1, further comprising administering an effective amount of at least one non-aldosterone antagonist agent.

24. The method of claim 23, wherein said at least one non-aldosterone antagonist agent is chosen from beta-blockers;

angiotensin II receptor blockades;

angiotensin converting enzyme inhibitors;

statins;

triglycerides lowering agents;

niacin;

diabetes agents;

immunomodulators;

nicotine;

sympathomimetics;

antihistamines;

cholinergics;

acetylcholinesterase inhibitors;

magnesium and magnesium sulfates;

calcium channel blockers;

muscarinics;

sodium channel blockers;

glucocorticoid receptor blockers;

peripheral andrenergic inhibitors;

blood vessel dilators;

central agonists;

combined alpha and beta-blockers;

alpha blockers;

combination diuretics;

cyclic nucleotide monophosphodiesterase (“

PDE”

) inhibitors;

alcohols;

vasopressin inhibitors;

oxytocin inhibitors;

glucagons like peptide 1;

relaxin hormone;

renin inhibitors;

estrogen compounds;

progesterone inhibitors;

testosterone inhibitors;

gonadotropin-releasing hormone analogues (GnRH-As);

gonadotropin-releasing hormone inhibitors;

vesicular monoamine transport (VMAT) inhibitors;

dipeptidyl peptidase (DP) IV inhibitors;

dhea;

melatonin;

anti-coagulants;

hmg1 antagonists;

leptin;

Galanin like peptide;

beta agonists;

alpha agonists;

indirect agents that include norepinephrine, epinephrine;

norepinephrine;

acetylcholine;

acetylcholine analogues);

sodium;

calcium;

angiotensin I;

angiotensin II;

angiotensin converting enzyme I (“

ACE I”

);

angiotensin converting enzyme II (“

ACE II”

);

aldosterone;

potassium channel blockers and magnesium channel blockers, e.g., valproate (sodium valproate, valproic acid), lithium;

cocaine;

amphetamines;

ephedrine;

terbutaline;

dopamine;

doputamine;

antidiuretic hormone;

oxytocin;

THC cannabinoid compounds;

progsterone.

62. An algorithm for administering said at least one aldosterone antagonist to said subject according to the method of claim 1 recorded on a computer-readable medium.

63. A system comprising:

(a) an algorithm for administering said at least one aldosterone antagonist to said subject according to the method of claim 1 recorded on a computer-readable medium

(b) a pharmaceutically effective amount of at least one aldosterone antagonist, and

(c) a drug delivery device.

11-19. -19. (canceled)

25-61. -61. (canceled)

64-67. -67. (canceled)